Dren Bio and Sanofi Forge ~$1.8B Deal to Advance Next-Generation B-Cell Depletion Therapy

Shots: Dren Bio has partnered with Sanofi to discover & develop next-generation B-cell depleting therapy for the treatment of various autoimmune diseases As per the deal, Dren Bio will receive $100M upfront & ~$1.7B in milestones, with both parties jointly leading discovery & preclinical work using Dren Bio’s platform, after which Sanofi will handle…

ByRidhi RastogiDecember 16, 2025

BioArctic and Novartis sign agreement for BrainTransporter ~$802M

Shots: BioArctic has entered into an option, collaboration, and license agreement with Novartis to develop a neurodegeneration treatment using BrainTransporter As per the deal, BioArctic receives $30M upfront and could earn up to $772M in milestones plus tiered mid-single-digit royalties if Novartis licenses and commercializes the drug BioArctic will develop a drug candidate using BrainTransporter and a Novartis…

ByDipanshu DixitAugust 26, 2025

Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders

Shots: Ono Pharmaceutical entered into an option agreement to obtain exclusive rights for identified small-molecule compounds developed by leveraging Reborna’s proprietary RNA-targeting drug discovery platform Furthermore, the companies will collaborate to discover small molecule drug candidates for mutually selected rare neurological disorders Upon exercising the option, Ono will gain exclusive worldwide rights to develop, manufacture, and…

ByRidhi RastogiApril 1, 2025

Dren Bio and Sanofi Forge ~$1.8B Deal to Advance Next-Generation B-Cell Depletion Therapy

BioArctic and Novartis sign agreement for BrainTransporter ~$802M

Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders

Contact US

OUR INFORMATION

FOLLOW US